Authors
Jianing Pei, Changye Lu, Tian Zeng, Yang Zhao, Chen Chen, Jingjing Wang, Yugen Chen, Xiaomin Yuan
Published in
iScience. Volume 29. Issue 11. Pages 118141. Nov 20, 2026. Epub Nov 05, 2026.
Abstract
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disorder characterized by gut dysbiosis and recurrent intestinal inflammation. Integrating bibliometric analysis, two-sample Mendelian randomization (MR), cross-platform protein pQTL MR, colocalization, and druggability assessment, we dissected gut microbiota-driven plasma metabolite-inflammation homeostasis axes in IBD. MR and mediation analyses identified multi-omics biomarkers and 24 candidate therapeutic metabolites organized into three regulatory axes: Klebsiella-glycine-β-muricholic acid (Gly-β-MCA)-CCL20/IL-10RA, Clostridium sp CAG-632-lauroyl-L-carnitine chloride-IL-10/IL-8, and Treponema-4-vinylphenol-IL-10RA. In RAW 264.7 macrophages and dextran sulfate sodium (DSS)- and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis models in mice, the three metabolites suppressed pro-inflammatory cytokine expression, with Gly-β-MCA showing the strongest effect and lauroyl-L-carnitine chloride upregulating IL-10 to alleviate Crohn's-like colitis. These findings help clarify multi-omics causal relationships in IBD and support precision anti-inflammatory therapy via metabolite-inflammation axes.
PMID:
43034714
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0